Allopurinol

Allopurinol and febuxostat were both associated with lower all-cause mortality when used by adults undergoing hemodialysis in Japan; allopurinol also lowered risk of death from CVD events, according to study data.

When initiating allopurinol for gout under a “start low, go slow” dosing strategy, flares in the first 6 months are most common in patients starting with 100 mg daily, or who flared in the month before beginning therapy, according to data.

Approximately 26% of patients with gout are commonly prescribed colchicine prophylaxis despite already using medications with potential interactions, according to data published in Rheumatology.

Starting urate lowering therapy during a gout flare does not impact the flare’s severity, duration or risk for recurrence over the following month, according to a systematic review and meta-analysis.

A 70-year-old Korean-born man calls in on Monday morning to make an appointment for an evaluation of acute joint pain, which started yesterday. He is in a significant amount of pain and would like to be seen today if possible.

Following a major price increase in 2010, the use of colchicine for gout declined while rheumatology and emergency department visits for the disease increased, according to data published in JAMA Internal Medicine.

Allopurinol compared with usual care in patients with ischemic heart disease.

In patients with ischemic heart disease older than 60 years, the uric acid-lowering drug allopurinol did not improve CV outcomes, according to results of the ALL-HEART trial presented at the European Society of Cardiology Congress.

All around the world, gout prevalence is growing at an alarming pace, while gout treatment remains as “horribly mismanaged” as ever.